At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Massachusetts based CFO’ operating in the Biotechnology space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected].
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Lee Kalowski
Chief Financial Officer of Bicycle Therapeutics
Lee has served as chief financial officer at Tokai since September 2014. Prior to joining Tokai, he served as a vice president in global biotechnology equity research at Credit Suisse. In this role, Lee served as a senior research analyst covering the biotechnology industry, including numerous companies globally in the prostate cancer therapeutic area. Prior to Credit Suisse, Lee worked at Johnson & Johnson in mergers & acquisitions in the pharmaceutical group, where he was involved in the analysis and execution of several completed transactions, and in global pharmaceutical equity research at Sanford C. Bernstein and Prudential Equity Group. Lee holds a B.A., Phi Beta Kappa, in biology and economics, from Union College and an M.B.A. in finance and health care management from the Wharton School, University of Pennsylvania.
Follow Lee Kalowski:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Chuck Carelli
CFO of Flagship Pioneering
Chuck Carelli, CPA, joined Flagship Ventures in 2009 with 16 years of experience in financial accounting, reporting and management. After obtaining his CPA license while working in the Boston office of Deloitte & Touche, Chuck spent 13 years in various senior financial accounting and management roles at three Massachusetts-based publicly traded biotech companies. From 2004 until joining Flagship, he served in various senior financial roles with EXACT Sciences, most recently as Chief Financial Officer. Previously he was with Alkermes, Inc. serving first as Controller then as Director of Finance. He also served as Accounting Manager and then Director of Accounting at Creative BioMolecules. As CFO, Chuck is responsible for all of Flagship Ventures’ financial and tax reporting, cash flow management, fund audits, and financial administration, as well as the financial operations of Flagship’s VentureLabsTM unit. Chuck holds a BA in Accounting from Assumption College.
Follow Chuck Carelli:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Sravan K. Emany
SVP & Chief Financial Officer of Ironwood Pharmaceuticals
Sravan K. Emany is Chief Financial Officer at Ironwood. Before joining the company in 2021, Mr. Emany served as the Corporate Vice President, Commercial Excellence and Chief Strategy Officer at Integra Lifesciences Holdings Corporation, where he was responsible for the Company’s commercial support functions and led the development of their corporate strategy. Prior to Integra, Mr. Emany was at Bank of America for ten years and held roles of increasing responsibility within the Mergers & Acquisitions (M&A) business, ultimately serving as a Managing Director of the M&A group. Mr. Emany began his career working at several well-respected banking institutions including Morgan Stanley and Goldman Sachs. Mr. Emany has a B.A. in international relations and an M.A. in international relations and international economics, both from Johns Hopkins University.
Follow Sravan K. Emany:
About Ironwood Pharmaceuticals: Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, develops drugs for gastrointestinal and cardiovascular diseases.
Jeanne Henry
CFO of Excel Venture Management
Jeanne joined the Excel team in 2009 and brings more than 18 years of venture capital financial management and reporting experience to the team. Previously, Jeanne was CFO and most recently COO with Atlas Venture, an international venture firm. Earlier she was an Audit Manager with Coopers & Lybrand (now PricewaterhouseCoopers). Jeanne holds a B.A. from the University of New Hampshire, an MBA from the University of Illinois, Chicago and is a Certified Public Accountant. She is a member of the AICPA, the M.A. Society of CPA’s, and a former Board member of the Private Equity CFO Association.
Follow Jeanne Henry:
About Excel Venture Management: Excel Venture Management builds companies that apply transformative life science technologies to solve problems in healthcare and beyond.
Kevin Gillis
CFO / Partner of Third Rock Ventures
Kevin Gillis joined Third Rock Ventures in 2008 and oversees the operational, financial and administrative aspects of the firm. He also directs and oversees the initial operational activities for our portfolio companies. Kevin has approximately 20 years of financial experience, successfully designing, overseeing and managing the financial operations for both newly emerging and established biotech companies. Prior to joining Third Rock Ventures, Kevin was Vice President of Finance at Coley Pharmaceutical Group, supporting the company’s successful initial public offering in 2005 and overseeing the finances related to the company’s acquisition by Pfizer in 2008. Prior to Coley, Kevin served in a number of senior finance roles at Millennium Pharmaceuticals and The Coca-Cola Company. Kevin holds an MBA from Bentley University and a BA from Brandeis University.
Follow Kevin Gillis:
About Third Rock Ventures: Third Rock Ventures invests in transformational life science companies that show high growth potential
Ommer Chohan
Chief Financial Officer of Atlas Venture
Ommer Chohan joined Atlas in 2015 and servers as the firm’s Chief Financial Officer. He oversees the firm’s financial, legal, and operations functions. Prior to joining Atlas, Ommer was CFO/COO at Summerhill Venture Partners. Ommer joined Summerhill in 2006 and was part of the original team that spun out the firm from Bell Canada. At Summerhill Ommer was responsible for the finance, IT, and administrative functions in addition to providing financial and legal support to the investment team. Prior to Summerhill, Ommer was the VP-Finance at First Asset Management Inc. (acquired by Affiliated Managers Group), a holding company with equity interests in several leading Canadian asset management firms. Ommer received his BA-Honours, Specialist in Management from the University of Toronto, his MBA from the Johnson School at Cornell University, and earned his CPA (Ontario) while at PricewaterhouseCoopers.
Follow Ommer Chohan:
About Atlas Venture: Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.
Brent Faduski
CFO of SV Health Investors
Brent Faduski joined SVLS in October 2008 as Controller and focuses on finance and accounting matters for the firm. Prior Experience: Prior to joining SVLS, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible for the accounting and finance aspects of the firm. Prior to joining CMGI @Ventures, Brent was a Senior Associate in the Technology Group at PricewaterhouseCoopers where his clients included early stage venture backed companies as well as venture capital funds.
Follow Brent Faduski:
About SV Health Investors: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Brent Faduski
CFO of SV Health Investors
Brent Faduski joined SVLS in October 2008 as Controller and focuses on finance and accounting matters for the firm. Prior Experience: Prior to joining SVLS, Brent was the Controller at CMGI @Ventures, the venture capital affiliate of CMGI, where he was responsible for the accounting and finance aspects of the firm. Prior to joining CMGI @Ventures, Brent was a Senior Associate in the Technology Group at PricewaterhouseCoopers where his clients included early stage venture backed companies as well as venture capital funds.
Follow Brent Faduski:
About SV Health Investors: SV Health Investors is a Boston-based venture capital firm focused on investments in biotechnology and healthcare industry.
Linda C. Bain
CFO of Codiak Biosciences
Linda C. Bain, CPA, has served as our vice president of finance and business operations since October 2011 and as our treasurer since March 2013. Previously, she served as vice president of corporate finance at Genzyme from September 2008 to September 2011, at Fidelity Investments from September 2007 to September 2008 and a number of positions at AstraZeneca from May 2000 to September 2007. She received her B.S. from the University of the Orange Free State in South Africa.
Follow Linda C. Bain:
About Codiak Biosciences: Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics.
David Socks
Co-founder, CFO, and CBO of HilleVax
Follow David Socks:
About HilleVax, Phathom Pharmaceuticals: HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines.
Peter Aranow
Chief Financial Officer of Respiratory Motion
Mr. Aranow is the Chairman of Boynton Angels, a Worcester investor group that invests in start-up companies. Peter Aranow has spent 30 years in finance. For 17 years he was in the investment banking department of Bear Stearns & Co., where he worked on debt and equity financings, mergers and acquisitions, and was the investment banker responsible for Bear Stearns’ initial public offering. For the following 13 years he served as chief financial officer for a number of public and privately-owned companies, including an Internet advertising company and the New York City Off-Track Betting Corporation. Mr. Aranow holds an BA from Harvard College and an MBA from Harvard Business School.
Follow Peter Aranow:
About Harvard Business School Community Action Partners, Off Track Betting New York, Respiratory Motion: Respiratory Motion ExSpiron is FDA and CE Mark cleared and non-invasively measures minute ventilation, the fundamental unit of breathing.
Kimi Iguchi
CFO of SAGE Therapeutics
Kimi Iguchi joined SAGE Therapeutics in March 2013 as Chief Financial Officer with more than 15 years of progressive experience managing finance, accounting, operations and human resources in emerging life science companies. Prior to joining SAGE, Ms. Iguchi has led the organizational development of strategic business plans, portfolio management, deal structure, fund raising, financial planning, and operations infrastructure design and growth. She has held positions at Warp Drive Bio, LLC, Santhera Pharmaceuticals, Cyberkinetics, Millennium Pharmaceuticals and Biogen, Inc. She began her career at PricewaterhouseCoopers LLP, Boston. Ms. Iguchi holds a B.A. in chemistry from Drew University, received her MBA from Northeastern University, and earned her CPA in Massachusetts.
Follow Kimi Iguchi:
About SAGE Therapeutics: SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.
Mary Reumuth
Chief Financial Officer of Kala Pharmaceuticals
Ms. Reumuth joined Kala in February of 2014 as Senior Director, Finance and Corporate Controller. She brings with her nearly 20 years of diversified finance and accounting experience. Ms. Reumuth was formerly Corporate Controller for Enobia Pharma (acquired by Alexion Pharmaceuticals). Prior to her tenure at Enobia, she spent several years at Genzyme Corporation in Cambridge, MA through the acquisition of ILEX Oncology in San Antonio, Texas. Ms. Reumuth began her career as an auditor with the San Antonio office of Ernst & Young LLP. Ms. Reumuth earned her business degree from Texas A&M University – Corpus Christi and is a Certified Public Accountant.
Follow Mary Reumuth:
About Kala Pharmaceuticals: Kala Pharmaceuticals develops novel treatments for diseases that affect mucosal tissues.
Edward Freedman
Chief Financial Officer of Faze Medicines
Ed is head of operations focusing on firmwide operations and providing financial, legal and operational guidance and support to Atlas’ seed stage companies. Ed has more than 20 years of leadership experience directing finance, legal and operations activities in companies across multiple industries. Prior to joining Atlas in 2018, Ed served as CFO at both KSQ Therapeutics and XTuit Pharmaceuticals. Prior to KSQ and XTuit, Ed was CFO and general counsel at Oasys Water, a global technology company in the energy and natural resource industries. Ed previously served as general counsel of Flagship Ventures (now Flagship Pioneering) and started his legal career at Testa, Hurwitz & Thibeault, LLP. Before going to law school, Ed was an accountant at Arthur Andersen & Co. Ed earned his JD from Boston College Law School and his BSBA in Accounting from Boston University.
Follow Edward Freedman:
About Faze Medicines, Freedman Advisors, Pandion Therapeutics: Faze Medicines is a biotechnology company.
Jeff Poulton
Chief Financial Officer of Alnylam Pharmaceuticals
Follow Jeff Poulton:
About Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Michael A. Doyle
Chief Financial Officer of Quanterix
With nearly 30 years of financial and management experience at major companies, Michael serves as Forrester’s chief financial officer (CFO). He leads Forrester’s finance team and oversees the company’s relationships with investors, market analysts, accountants, and bankers. Michael’s responsibilities also include both managing day-to-day financial activity as well as planning for Forrester’s long-term opportunities. Prior to joining Forrester, Michael was CFO of EasyLink Services, a publicly traded global telecommunications messaging provider. There he led an organization focused on improving productivity and financial planning and reporting. Previously, Michael served as CFO at Dun & Bradstreet, North America, responsible for driving the cash flow process improvement to record cash performance, and successfully integrating the Hoovers acquisition. Michael began his career at Continental Can where his tenure included financial management roles at the leading diversified packaging manufacturer. For the next 14 years, he held senior financial management positions at Cendant, Allied Signal, PepsiCo, as well as marketing and strategy positions at Cendant and PepsiCo. Michael holds a Master of Business Administration from New York University and a Bachelor of Business Administration in finance from the University of Notre Dame.
Follow Michael A. Doyle:
About Quanterix: Quanterix is a platform for single molecule analysis that supports clinical diagnostics, drug development, and life science researches.
Fred Driscoll
Chief Financial Officer of Flexion Therapeutics
Fred Driscoll has more than 20 years of experience in financial management of life sciences companies, most recently as the Chief Financial Officer at Flexion Therapeutics, Inc., where he spearheaded an initial public offering in 2014. Prior to joining Flexion, he served as Chief Financial Officer at Novavax, Inc. from 2009 to 2013. From 2008 to 2009, Fred Driscoll served as Chief Executive Officer of Genelabs Technologies, Inc., a publicly traded biopharmaceutical and diagnostics company later acquired by GlaxoSmithKline. Prior to serving as Chief Executive Officer of Genelabs he was the Chief Financial Officer from 2007 to 2008. From 2000 to 2006, Fred Driscoll served as Chief Executive Officer at OXiGENE, Inc., where he also served as Chairman of the Board and Audit Committee Chair. He was also a member of the Audit Committee for Cynapsus Therapeutics, Inc., which was sold to Sunovion Pharmaceuticals in 2016. Fred Driscoll earned a B.S. in accounting and finance from Bentley University. He is a member of the board of directors of Cellectar Biosciences, Inc., MEI Pharma, Inc. and NantKwest, Inc.
Follow Fred Driscoll:
About Flexion Therapeutics: Flexion Therapeutics is a biotechnology company that develops long-lasting intra-articular injection therapies to treat osteoarthritis.
Frank Reynolds
Chairman of the Board, CEO, CFO, CSO & Co-Founder of PixarBio
Follow Frank Reynolds:
About PixarBio: PixarBio Corp is a specialty Biotechnology company focused on pre-clinical and commercial development of new products.
Hunter Smith
Chief Financial Officer of Rhythm Pharmaceuticals
Hunter Smith is the Chief Financial Officer at Rhythm Pharmaceuticals.
Follow Hunter Smith:
About Rhythm Pharmaceuticals: Rhythm is a biopharmaceutical company focused on developing and commercializing peptide therapeutics
Kam Unninayar
CFO of Tetraphase Pharmaceuticals
Follow Kam Unninayar:
About Tetraphase Pharmaceuticals: Tetraphase Pharmaceuticals is a company leveraging a dynamic drug engine targeted at several significant disease categories.
Gregory Weaver
Chief Financial Officer of Eloxx
Greg Weaver joined PLI as CFO in November 2015. Greg is an experienced CFO and board director, having served in executive positions with biopharma companies in the US and Europe. Most recently he served as CFO and board director with Oryzon Genomics in Boston and Barcelona, and previously has served as CFO with the following Nasdaq-listed public biotech companies: Fibrocell, Celsion, Poniard, Sirna, Nastech, and ILEX. Greg currently serves on the boards of public biotech companies Egalet, and Atossa Genetics. Greg has led the raise of over US$800 million in various financing transactions throughout his career, and has led companies through IPO, drug development, and revenue growth, while positioning a number of companies for successful acquisition. Greg began his career as a CPA with Arthur Andersen, with an MBA from Boston College and BS in accounting from Trinity University.
Follow Gregory Weaver:
About Eloxx: Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates.
Nikita Shah
President & CFO of Nivien Therapeutics
Follow Nikita Shah:
About General Biotechnologies, Nivien Therapeutics: Nivien Therapeutics is developing the first small molecule drugs to enhance both chemo and immunotherapies.
Ian C. Sanderson
CFO of Nimbus Therapeutics
Follow Ian C. Sanderson:
About Boston Pharmaceuticals, Nimbus Therapeutics: Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.
Daniella Beckman
CFO of Tango Therapeutics
Daniella Beckman has served as the senior vice president, chief financial officer and treasurer of Idenix since March 2012 and the vice president, chief financial officer and treasurer since June 2011. Daniella Beckman served as the interim chief financial officer and treasurer of Idenix from October 2010 to June 2011 and as the corporate controller of Idenix from March 2008 to October 2010. Before joining Idenix, Daniella Beckman held positions at Coley Pharmaceutical Group, most recently as corporate controller. Prior to Coley, Daniella Beckman also held positions at Biogen Idec from September 2004 through March 2006 as well as PricewaterhouseCoopers from September 2000 through September 2004. Daniella Beckman holds a B.A. from Boston University and is also a Certified Public Accountant (CPA).
Follow Daniella Beckman:
About Tango Therapeutics: Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Chip Catlin
Senior Vice President and Chief Financial Officer of Celldex Therapeutics
Chip Catlin joined our board of directors in September 2018. He currently serves on the Board of Corbus Pharmaceutical Holdings, Inc. Chip Catlin previously served as Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc., where he raised more than $500 million from equity, convertible debt and private placement transactions, as well as devised and led financial strategies to successfully complete several asset acquisitions adding substantial long term value for the company. Prior to Celldex, Chip Catlin held senior financial and operational positions with biopharma companies Endogen, Inc. and Repligen Corporation. Chip Catlin earned a B.A. in Psychology from the University of Virginia and an MBA from Babson College. He is also a certified public accountant. Chip Catlin’s more than 22 years of experience as a senior financial officer of public biopharmaceutical companies make him an ideal addition to our board of directors.
Follow Chip Catlin:
About Celldex Therapeutics: Celldex is a clinical stage company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases.
Chuck Abdalian
CFO of Checkmate Pharmaceuticals
Follow Chuck Abdalian:
About Checkmate Pharmaceuticals: Checkmate Pharma is a clinical stage biopharmaceutical company developing a new approach for cancer immunotherapy.
Grayson Allen
CFO/COO & Co-Founder of RevBio
Grayson oversees the financial planning and reporting function as Interim CFO at Maxwell Health, and is also involved in strategic and tactical matters related to Maxwell’s continued growth. Previously, Grayson served as the CFO of a venture-backed technology company where he led a team which oversaw all financial planning and reporting, accounting, information technology, and human resources functions at the company. He played a key role in raising more than $60 million in venture capital and implemented the infrastructure necessary for rapid growth. Grayson also served as CFO for a private equity owned company engaged in the design and manufacture of bridge cranes, gantry cranes, and other custom industrial material handling solutions. While there, Grayson played an instrumental role in executing a turnaround strategy which included reducing past due receivables by 71%, managing cash flow during a period of tight liquidity, renegotiating contract terms with customers and suppliers, and assisting in the recapitalization of the ownership structure. Previously, as a Principal at the $500 million private equity arm of a leading commercial bank holding company, he was a member of the team which structured and oversaw a portfolio consisting of private equity, venture capital, and fund-of-funds investments. Grayson started his career as a commercial loan underwriter. Grayson received his B.A. in History (high honors) from Dartmouth College and his M.B.A. from the Sloan School of Management at the Massachusetts Institute of Technology. Outside of work, Grayson enjoys being outdoors and active as much as possible, and likes sailing in the summer, hiking in the fall, and running throughout the year. For many years he has collected Asian art and artifacts and has been actively collecting Japanese woodblock prints since he was 12 years old. Both Grayson and his wife Lorraine enjoy cooking together and are always interested in trying out new recipes when they have the chance.
Follow Grayson Allen:
About RevBio: RevBio was started with one goal in mind—to end medicine’s 50-year search for a biocompatible bone adhesive.
C. Evan Ballantyne
Chief Financial Officer of OncXerna Therapeutics
C. Evan Ballantyne is the chief financial officer of [Agenus](https://www.crunchbase.com/organization/agenus), a biotechnology company that develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. Previously, he worked as the CEO of Synthetic Biologics. Ballantyne served as the CFO and executive vice president of Trovis Pharmaceuticals from 2006, before which he was the CFO of Knowledge Impact, ZymeQuest, Clinical Data, Velico Medical, Avalon Pharmaceuticals, and AcNielsen Corporation. Ballantyne holds a bachelor’s degree in political sciences and American history from the University of Western Ontario and a post-graduate degree in business administration from the University of Windsor.
Follow C. Evan Ballantyne:
About OncXerna Therapeutics: OncXerna Therapeutics offers precision medicine using an innovative RNA-based biomarker platform.
Joanne Bryce
Chief Financial Officer of Disc Medicine
Follow Joanne Bryce:
About Disc Medicine, Speedy Packets: Disc Medicine is a hematology company
Phil Gardella
CFO of Vizgen
Phil Gardella is the Chief Financial Officer at Vizgen.
Follow Phil Gardella:
About Vizgen: Vizgen is a biotech company that develops solutions for next-generation spatially resolved, single-cell transcriptomics.
Sylvia Cheung
Chief Financial Officer of Oculis
Sylvia Cheung is the Chief Financial Officer at Anika Therapeutics since April 1, 2013. Sylvia brings to Anika a substantial number of years of financial and general management experience. Prior to her current position, Sylvia was the Vice President of Strategic Processes and previously, she served as the General Manager for the company’s Italian-based subsidiary, Anika S.r.l. Sylvia joined Anika as Controller in 2005. In addition to fulfilling wide-ranging financial responsibilities as Controller, Sylvia led the company’s integration of Anika S.r.l. subsequent to its acquisition in 2009. Prior to Anika, she held a series of progressively responsible financial management positions at Transkaryotic Therapies, Inc. From 1995 to 2000, Sylvia worked for PricewaterhouseCoopers, LLP as an Audit Senior Associate. Sylvia holds a Bachelor of Business Administration degree in Accounting from the University of Massachusetts in Amherst, a Master’s degree in Business Administration from Boston University, and is a Certified Public Accountant (inactive).
Follow Sylvia Cheung:
About Oculis: Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery.
Ken Mace
Chief Financial Officer of Alzheon
Follow Ken Mace:
About Alzheon: Alzheon is a clinical-stage biotechnology company focused on brain health, memory and aging, developing a pipeline of innovative.
Richard Vellacott
Chief Financial Officer of Horizon Discovery
Richard has over 15 years’ experience as a chartered accountant, working with life science companies from start-ups to global pharmaceuticals. He also has a first class degree in biological sciences from Durham University. Past roles include Vice President, Finance at CSR plc, a listed hi-tech company with revenues of $1bn. During his time at CSR Richard had worldwide responsibility for finance, making significant contributions to the transformational acquisition and integration of a NASDAQ listed Zoran Corp., product portfolio management, R&D budgeting and business investment / divestment decisions. Before this, Richard was a Director in Deloitte’s life sciences practice, where he specialized in capital market transactions including IPOs, M&A and fundraising on both the UK and the US markets. Beyond his corporate responsibilities, Richard has advised the EC on funding for life science companies and presented at investor conferences and technical seminars on financial issues facing the life science industry.
Follow Richard Vellacott:
About Horizon Discovery: Horizon is a gene editing company that designs & engineers genetically-modified cells, applying them to advance human health.
Howard Liang
President and CFO of Tessera Therapeutics
Follow Howard Liang:
About Tessera Therapeutics: Tessera Therapeutics is an early-stage life sciences company.
Donald Notman
Chief Financial Officer of Ocular Therapeutix
Donald Notman brings over 20 years of financial operations and senior-level investment banking experience to Ocular Therapeutix. Prior to joining the company, Donald Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc., where he led the company’s financial operations, business development activities, and strategic planning functions. Previously, Donald Notman served as Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was involved in the build-out of the firm’s healthcare investment banking capabilities. Before joining Leerink, Donald Notman held senior level investment banking positions with Deutsche Banc Alex. Brown and Alex. Brown & Sons. Donald Notman received his M.B.A. from The Tuck School of Business at Dartmouth College and his B.A. in Economics from Middlebury College.
Follow Donald Notman:
About Ocular Therapeutix: Ocular Therapeutix develops and commercializes ophthalmic therapeutic products by using hydrogel technology.
Donald Notman
Chief Financial Officer of Ocular Therapeutix
Donald Notman brings over 20 years of financial operations and senior-level investment banking experience to Ocular Therapeutix. Prior to joining the company, Donald Notman served as Senior Vice President and Chief Financial Officer of Thrasos Therapeutics Inc., where he led the company’s financial operations, business development activities, and strategic planning functions. Previously, Donald Notman served as Managing Director and Head of Private Capital Markets for Leerink Swann LLC (now Leerink Partners), where he was involved in the build-out of the firm’s healthcare investment banking capabilities. Before joining Leerink, Donald Notman held senior level investment banking positions with Deutsche Banc Alex. Brown and Alex. Brown & Sons. Donald Notman received his M.B.A. from The Tuck School of Business at Dartmouth College and his B.A. in Economics from Middlebury College.
Follow Donald Notman:
About Ocular Therapeutix: Ocular Therapeutix develops and commercializes ophthalmic therapeutic products by using hydrogel technology.
Manmeet S. Soni
Chief Financial Officer of Reata Pharmaceuticals
CFO/EVP at Reata Pharmaceuticals.
Follow Manmeet S. Soni:
About Reata Pharmaceuticals, Reata Pharmaceuticals: Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Marc Schneebaum
Chief Financial Officer of Avalyn Pharma
Follow Marc Schneebaum:
About Avalyn Pharma: Avalyn Pharma is a biopharma company that advances therapies for the treatment of Idiopathic Pulmonary Fibrosis.
Nathan Jorgensen
Chief Financial Officer of Vor Biopharma
Nathan Jorgensen is the Chief Financial Officer at Vor Biopharma.
Follow Nathan Jorgensen:
About Vor Biopharma: Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Lynn Blake
CFO of SynerFuse
Lynn is the Chief Financial Officer of SynerFuse and Executive Vice President of State Street Global Advisors (SSGA) and CIO of Global Equity Beta Solutions. In this capacity, she oversees a team of 70 portfolio managers globally, and more than 1,600 portfolios with assets in excess of $1.4 trillion across all equity index and smart beta strategies. She also oversees SSGA’s Corporate Governance and Global Proxy Voting as well as the Company Stock Group which manages fiduciary transactions and company stock investments, including company stock ownership and 401K plans. In addition, she is a member of the SSGA Fiduciary Committee, the Investment Committee, and the IT Steering Committee. Lynn also serves as a member of SSGA’s Executive Management Group. Prior to her current role, Lynn was head of non-US markets of passive equities, responsible for overseeing the management of all non-US equity index strategies, as well as serving as portfolio manager for several equity index portfolios. She joined SSGA in 1987. Lynn has a Master of Business Administration in finance from Northeastern University, and a Bachelor of Science from the Boston College Carroll School of Management. She earned the Chartered Financial Analyst (CFA) designation and is a member of the CFA Institute and the Boston Security Analyst Society. She also serves on various index advisory boards and committees.
Follow Lynn Blake:
About State Street Global Advisors, SynerFuse: SynerFuse is a provider of traditional spine implants intended to offer long-term pain management without the use of addictive opioids
William J. Kelly
Chief Financial Officer of Exosome Diagnostics
Mr. Kelly has over 20 years of financial management experience, including 13 years leading growing, international, publicly traded life science companies. Prior to joining Exosome Diagnostics, Mr. Kelly served in executive positions such as Chief Financial Officer of RepliGen Corporation and Corporate Controller of Haemonetics. In such roles, Mr. Kelly oversaw corporate financial operations, including several successful acquisitions. Mr. Kelly began his financial career as an auditor at leading financial firms Deloitte & Touche and Ernst and Young. Mr. Kelly is a Certified Public Accountant who holds an M.S./M.B.A. from Northeastern University and a B.A. in psychology from the College of the Holy Cross.
Follow William J. Kelly:
About Deloitte, Exosome Diagnostics: Exosome Diagnostics develops and commercializes blood-based cancer molecular diagnostics for patient stratification and disease monitoring.
Eric Shaff
CFO of Seres Therapeutics
Eric Shaff has over 15 years of experience working in leadership roles in biotechnology finance, corporate development, and capital markets. He serves as the executive vice president and chief financial officer of [Seres Therapeutics](https://www.crunchbase.com/organization/seres-health#/entity), a therapeutics company engaged in the R&D of drugs for the treatment of microbiome diseases. Previously, Shaff was vice president of corporate finance at Momenta Pharmaceuticals, where he helped manage Momenta Pharmaceutical’s accounting, finance, planning, and procurement functions as well as contributing to Momenta Pharmaceutical’s investor relations efforts. Prior to joining Momenta Pharmaceuticals, he was the vice president of finance at Genzyme’s Rare Genetic Disease Division. Shaff held several positions in business unit finance, corporate finance, and corporate development at Genzyme. Before joining Genzyme, he worked in corporate finance at Pfizer and worked in investment banking for Broadview International. Shaff obtained his bachelor’s degree in political science and economics from the University of Pennsylvania and his MBA in finance from the Johnson Graduate School of Management at Cornell University.
Follow Eric Shaff:
About Seres Therapeutics: Seres Therapeutics is a microbiome therapeutics company focused on discovering and developing Ecobiotic therapeutic products.
Don Munoz
Chief Financial Officer of NuCana BioMed
Don Munoz is the Chief Financial Officer at NuCana BioMed.
Follow Don Munoz:
About NuCana BioMed: NuCana BioMed, a biopharmaceutical company, develops and commercializes rationally designed medicines for significant unmet medical needs.
Dan Sullivan
CFO of TruTouch Technologies
Follow Dan Sullivan:
About TruTouch Technologies: TruTouch Technologies manufactures noninvasive intoxication measurement systems that help measure a person’s alcohol concentration.
Ted Myles
Executive Vice President and Chief Financial Officer of AMAG Pharmaceuticals
Ted Myles joined ACT in June 2013, as the company’s Chief Financial Officer and Executive Vice President of Corporate Development. From November 2008 to June 2013 Ted Myles was with PrimeraDx, a privately-held molecular diagnostics company, where he served as Chief Financial Officer and Vice President of Operations. At PrimeraDx, Ted Myles helped to lead the company from the proof-of-concept stage to become a fully integrated commercial organization. Prior to joining PrimeraDx, Ted Myles was the Chief Financial Officer and Senior Vice President of Finance at Pressure BioSciences, a Nasdaq-listed, life-science tools company. Earlier in his career, Ted Myles held financial positions of increasing responsibility with EMD Pharmaceuticals (a subsidiary of Merck KGaA), SG Cowen Securities Corporation, Boston Biomedica and PriceWaterhouseCoopers. He received a master’s degree in business administration, with an emphasis on strategy and corporate finance, from Washington University in St. Louis and a bachelor’s degree in business administration from the University of Hartford. Ted Myles became a CPA in 1996.
Follow Ted Myles:
About AMAG Pharmaceuticals: AMAG Pharmaceuticals is a biopharmaceutical company, which utilizes the technology for the development and commercialization of therapeutic.
R. Scott Areglado
SVP and Chief Financial Officer of Brainsway
Scott Areglado is the SVP and Chief Financial Officer at BrainsWay.
Follow R. Scott Areglado:
About Brainsway, iCAD: Brainsway’s patented breakthrough technology launches a new era in brain disorder treatment.
William Duke
Chief Financial Officer of Kaleido BioSciences
William Duke has served as Kaleido’s Chief Financial Officer since November 2019. He joined Kaleido from Pulmatrix, Inc., a Nasdaq-listed, clinical-stage pulmonary therapeutics company where he was CFO. There, he oversaw the company’s financial strategy, helped negotiate the company’s first product partnership, and led the successful completion of several public offerings. Prior to Pulmatrix, he served as CFO of Valeritas, Inc., a commercial-stage medical technology company, where he led a private financing round, recapitalized the company, and was responsible for the strategic planning, development and leadership of the corporate finance function. Mr. Duke also was senior director of finance at Genzyme Corporation, helping in the sale of the company to Sanofi, and director of finance/accounting at Haemonetics Corporation. Earlier in his career he held CFO positions at G8wave, an integrated media company focused on mobile platforms, and OTF Group, Inc. a business strategy consulting firm. Mr. Duke earned his B.S. in Business Administration from Stonehill College, an M.B.A. from Bentley University, and is a certified public accountant.
Follow William Duke:
About Kaleido BioSciences: Kaleido BioSciences is a company working to design and analyze the microbiome system and provide adaptive solutions.
Sheng-kuei Hsu
COO/CFO & Co-founder of Coolso
Follow Sheng-kuei Hsu:
About Coolso: Coolso uses unique patent technology to develop wearable gesture recognition solution.
Sheng-kuei Hsu
COO/CFO & Co-founder of Coolso
Follow Sheng-kuei Hsu:
About Coolso: Coolso uses unique patent technology to develop wearable gesture recognition solution.
David Francisco
Chief Financial Officer of Organogenesis
David Francisco is the Chief Financial Officer at Organogenesis.
Follow David Francisco:
About Organogenesis: Organogenesis Inc. is a regenerative medicine company.
Michael Kaswan
Chief Financial Officer of Cognoptix
Michael Kaswan is the Chief Financial Officer at Cognoptix.
Follow Michael Kaswan:
About Cognoptix, Dune Medical Devices: Cognoptix develops non-invasive eye tests for the early diagnosis of alzheimer disease.